Staphylococcal infection
diseaseOn this page
Summary
Staphylococcal infection (MONDO:0024313) is a disease with 2 GWAS associations across 6 studies and 69 clinical trials. Top therapeutic interventions include clindamycin, cephalexin anhydrous, and daptomycin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 2
- Clinical trials: 69
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | staphylococcal infection |
| Mondo ID | MONDO:0024313 |
| EFO | EFO:1001849 |
| MeSH | D013203 |
| NCIT | C35038 |
| SNOMED CT | 56038003 |
| UMLS | C0038160 |
| MedGen | 52483 |
| Is cancer (heuristic) | no |
Also known as: staphylococcal infection
Data availability: 2 GWAS associations (6 studies).
Disease family
This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › staphylococcal infection
Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease
Subtypes (4): staphylococcus aureus infection, staphylococcal pneumonia, staphyloenterotoxemia, staphylococcal toxemia
Genetics & variants
GWAS landscape
2 GWAS associations across 6 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs144093950 | 2e-11 | POMP - SLC46A3 | T | 1.03 |
| rs117868031 | 2e-09 | CBFA2T3 - ACSF3 | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90477032 | Verma A | 2024 | 9,712 | 429,292 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90435519 | Zhou W | 2018 | 3,149 | 393,897 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90477031 | Verma A | 2024 | 2,393 | 116,104 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90479745 | Verma A | 2024 | 2,393 | 116,104 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477030 | Verma A | 2024 | 1,087 | 57,391 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651334 | Liu TY | 2025 | 198 | 213,110 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 2 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 1 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 2 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs144093950 | 13 | 28697535 | T>C | 0.003 | intergenic_variant | POMP - SLC46A3 | 2e-11 | Tier 4: intronic/intergenic |
| rs117868031 | 16 | 89057311 | A>G | intergenic_variant | CBFA2T3 - ACSF3 | 2e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
1 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Retapamulin | Approved (phase 4) |
| Ceftazidime | Phase 3 (in late-stage trials) |
| Telavancin | Phase 3 (in late-stage trials) |
| Vancomycin | Phase 3 (in late-stage trials) |
Clinical trials & evidence
Clinical trials
Clinical trials: 69.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 27 |
| PHASE4 | 12 |
| PHASE3 | 10 |
| PHASE1 | 10 |
| PHASE2 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05899140 | PHASE4 | RECRUITING | Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial |
| NCT06848387 | PHASE4 | RECRUITING | Unbound Cloxacillin Concentrations During Continuous Infusion |
| NCT00108160 | PHASE4 | COMPLETED | Preventing Staphylococcal (Staph) Infection |
| NCT00156377 | PHASE4 | COMPLETED | Prophylaxis With Intranasal Mupirocin for Prevention of S. Aureus Infections |
| NCT00352612 | PHASE4 | COMPLETED | Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections |
| NCT00368498 | PHASE4 | UNKNOWN | A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concentration Timely |
| NCT00419991 | PHASE4 | COMPLETED | Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection |
| NCT00423982 | PHASE4 | UNKNOWN | Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty |
| NCT01196169 | PHASE4 | TERMINATED | Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty |
| NCT02284555 | PHASE4 | COMPLETED | Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment) |
| NCT02899702 | PHASE4 | WITHDRAWN | Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children |
| NCT04141787 | PHASE4 | UNKNOWN | Ceftriaxone as Home IV for Staph Infections |
| NCT00071214 | PHASE3 | COMPLETED | Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis |
| NCT00130260 | PHASE3 | TERMINATED | Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease |
| NCT00211900 | PHASE3 | COMPLETED | Evaluation of Manufacturing Lot of StaphVAX |
| NCT00211913 | PHASE3 | COMPLETED | StaphVAX in Cardiovascular Surgery Patients |
| NCT00211926 | PHASE3 | COMPLETED | StaphVAX Immunogenicity in Orthopedic Implant Patients |
| NCT00211965 | PHASE3 | COMPLETED | StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery |
| NCT00211991 | PHASE3 | COMPLETED | Evaluation of Consistency of StaphVAX Manufacturing Lots |
| NCT00217841 | PHASE3 | COMPLETED | Aurograb and Vancomycin in MRSA Infection |
| NCT00427076 | PHASE3 | COMPLETED | Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections |
| NCT00729937 | PHASE2/PHASE3 | COMPLETED | Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus STOP MRSA |
| NCT00770341 | PHASE3 | COMPLETED | A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) |
| NCT02664740 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus |
| NCT00063089 | PHASE1/PHASE2 | COMPLETED | Safety and Behavior of S. Aureus Immune Globulin Intravenous(Human), [Altastaph] in Patients With S. Aureus Bacteremia and Continuing Fever |
| NCT00066989 | PHASE2 | COMPLETED | Safety Study of an Intravenous Staphylococcus Aureus Immune Globulin (Human), [Altastaph] in Low-Birth-Weight-Neonates |
| NCT00509847 | PHASE1/PHASE2 | WITHDRAWN | A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Bacteremia Due to S. Epidermidis |
| NCT00730028 | PHASE2 | COMPLETED | Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus |
| NCT01144000 | PHASE2 | UNKNOWN | Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection |
| NCT01827358 | PHASE2 | COMPLETED | Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants |
| NCT02492958 | PHASE2 | COMPLETED | SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults |
| NCT03915470 | PHASE2 | COMPLETED | Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection |
| NCT00303069 | PHASE1 | COMPLETED | V710 First-In-Man (FIM) Study (V710-001) |
| NCT00735839 | PHASE1 | COMPLETED | V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED) |
| NCT01018641 | PHASE1 | COMPLETED | An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults |
| NCT01273922 | PHASE1 | COMPLETED | Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida |
| NCT01324440 | PHASE1 | COMPLETED | Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002) |
| NCT01364571 | PHASE1 | COMPLETED | Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years |
| NCT01447407 | PHASE1 | COMPLETED | Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine |
| NCT01592214 | PHASE1 | COMPLETED | Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CLINDAMYCIN | 4 | 13 |
| CEPHALEXIN ANHYDROUS | 4 | 6 |
| DAPTOMYCIN | 4 | 3 |
| MUPIROCIN | 4 | 3 |
| VANCOMYCIN | 4 | 3 |
| ALBUMIN HUMAN | 4 | 1 |
| CEFAZOLIN | 4 | 1 |
| CEFTRIAXONE | 4 | 1 |
| CHLORHEXIDINE GLUCONATE | 4 | 1 |
| TIGECYCLINE | 4 | 1 |
| AUROGRAB | 3 | 1 |
| CO-TRIMOXAZOLE | 3 | 1 |
| TEICOPLANIN | 3 | 1 |
| EXEPORFINIUM CHLORIDE | 2 | 1 |
| CHEMBL1649722 | 0 | 3 |
| CHEMBL4286784 | 0 | 3 |
| CHEMBL4299436 | 0 | 3 |
| CHEMBL4744444 | 0 | 3 |
| CHEMBL4793658 | 0 | 2 |
| CHEMBL2105779 | 0 | 1 |
| CHEMBL2367892 | 0 | 1 |
| CHEMBL1628 | 0 | 1 |
| TEICOPLANIN A2-3 | -1 | 1 |